Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
This study has been completed.
Study NCT00211497   Information provided by MIGENIX Inc.
First Received: September 13, 2005   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acne Vulgaris
Acne
Propionibacterium Acnes
More general conditions related to this trial
Acneiform Eruptions
Facial Dermatoses
Sebaceous Gland Diseases
Skin Diseases
Interventions listed in this trial
MBI 226 Acne Solutions
Sponsors listed in this trial
MIGENIX Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services